Seeking Alpha

Novartis (NVS): Q2 adjusted earnings -2% to $3.23B vs consensus of $3.22B; EPS -4% to $1.30 vs...

Novartis (NVS): Q2 adjusted earnings -2% to $3.23B vs consensus of $3.22B; EPS -4% to $1.30 vs $1.34; net sales +1% to $14.49B vs $14.31B. Raises FY guidance due to Ranbaxy's failure to launch a generic version of Novartis' Diovan blood-pressure drug, and now expects core earnings to decline in the low single digits vs a mid-single digit drop previously forecast, and low single-digit sales growth vs flat previously. The impact of generic Diovan is expected in 2014. Hasn't been contact by China amid investigations in the healthcare sector. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|